LifeSci Capital LLC’s Post

Unlock the potential of light scattering techniques in quality control and development processes of mRNA-LNP therapeutics. Join our webinar tomorrow, May 7th, to gain an edge in your research.

A new year and a new adventure. In 2007, while a grad student at Caltech, I dreamt up an idea for a new kind of RNAi drug that could use non-target RNA strands in the cell as signals for activation. That idea became a project with the support of William Goddard, and then a conviction and pursuit when Bill and I met John Rossi and Lisa Scherer. The science became grounded in therapeutic applications when Saumya Das joined our team, and took off into a company when we partnered with Dee Datta, Ph. D. to found Switch Therapeutics. Over the past three years, Switch has made amazing strides in building the CASi platform and advancing it towards the clinic. What’s even more heartening to me, is that we now have a team of extremely talented and dedicated scientists and leaders within the company who understand CASi at a fundamental level and know how to carry the scientific vision forward. Furthermore, Switch is surrounded by a deep bench of advisors who bring tremendous knowledge and insights in support, and a wonderful group of investors who have stood with us through thick and thin. The strength of Switch has given me the opportunity to consider new vistas for the first time in more than a decade. Over the past year, I have been reconnecting with old friends from my grad school days in Bill Goddard’s group and discussing the impact of astonishing advances in generative artificial intelligence on science and technology. What emerged is a shared conviction that revolutionary new approaches are now on the verge of overcoming obstacles vexing the field of molecular simulations for the past 30 years.  What awaits us just on the other side are vast new commercial opportunities in drugs and materials. A team of old friends coalesced around this vision, and we decided to launch a new venture with me as co-founder and CEO. So, last year, I made the difficult decision of stepping down as CTO and changing to an SAB role at Switch. During the search process for my successor, we talked to a number of incredibly talented colleagues in the oligonucleotide therapeutics field. Ultimately, I am beyond pleased that Charles Allerson answered the call. Chuck brings more than 20 years of experience in oligonucleotide therapeutics and tremendous knowledge in RNA medicinal chemistry that will help take CASi to the next level. I am super excited to help him and Switch advance CASi in the coming years and look forward to more amazing progress from the team in 2024. In the coming months, I look forward to sharing more about newco, but today, the day belongs to Chuck and Switch. Congratulations Chuck! Thank you so much for coming aboard. Look forward to helping any way I can as you settle in the new role.

The post-operation recovery process can be complex, taking as little as a few weeks to several months for a full recovery. We’ve created devices that can help improve your body’s ability to recover at an increased speed without being intrusive. Trust your post-op recovery to Gladiator Therapeutics. https://ow.ly/ccfP50PS5bL

AsclepiX Therapeutics, Inc. has announced that it has secured a $10 million Series A-3 financing. The round was led by Perceptive Advisors with participation from the existing investors Hibiscus Capital Management Fund II and Rapha Capital Management, LLC and its managed fund, Rapha Capital Management, LLC PE Life Sciences Fund VI, in addition to a new outside investor. The lead clinical candidate, integrin regulating peptide AXT107 (gersizangitide), has a novel mechanism of action that inhibits neovascularization, reduces vascular permeability, and suppresses vascular inflammation. In a microparticulate suspension, AXT107 may be capable of maintaining sustained biological activity with one injection well beyond current standard of care. https://bit.ly/3rH7VZw

With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers

The Future of Exosome Based Therapeutics: Key Clinical Updates ZEO ScientifiX™ invites you to a LIVE Webinar on The Future of Exosome Based Therapeutics with Dr. George Shapiro, MD https://lnkd.in/g5pnyr42

Today, Halia Therapeutics announced that David Bearss Ph.D., President and CEO of Halia, will be presenting and participating in a panel discussion at the 5th Inflammasome Therapeutics Summit. The Summit is taking place on November 28-30, in Boston, MA. To read the full release, visit: https://prn.to/49NjLTM #inflammasome #chronicinflammation #NLRP3 #therapeutics #halia #newsrelease #therapeuticssummit

On Thursday, March 7, Poseida Therapeutics, Inc. released its Q4 and FY 2023 business updates (press release: https://bit.ly/3v5kKz3) highlighting clinical results from its lead asset P-BCMA-ALLO1’s (allogeneic #BCMA CAR-T) Ph1 trial (https://bit.ly/4ac3Ux8) in r/r MM and an initial readout from its P-MUC1C-ALLO1’s Ph1 trial (https://bit.ly/3ThM0SO) in advanced or metastatic solid tumors will be presented at #AACR24. Additionally, on Monday, March 11, Legend Biotech held its Q4 and FY 2023 earnings call (presentation: https://bit.ly/3VhMEmc / press release: https://bit.ly/3V977tg) reporting Carvykti’s (Johnson & Johnson / Legend Biotech’s BCMA CAR-T) revenue, while noting the doubling of its manufacturing capacity in 2023. Celltelligence provides insights on Poseida’s upcoming data presentation from its #celltherapy assets, while discussing Legend’s preparedness for anticipated #Carvykti entry in the second-line MM setting...: https://bit.ly/CT-861179

Repotrectinib: Why BMS Brought Turning Point for $4.1B | https://lnkd.in/g68-wgU5 In 2022, Turning Point Therapeutics was acquired by Bristol Myers Squibb for a whopping $4.1 billion in cash. Turning Point’s most advanced molecule at the time was repotrectinib, a potential best-in-class ROS1/TRK/ALK tyrosine kinase inhibitor then in Ph. I/II studies for cancer. Prior to the acquisition, the molecule had shown impressive activity in the clinic, with a median duration of response of over 30 months and activity in many patients who have failed on other drugs. As BMS anticipated, on Nov. 15, 2023, the FDA granted repotrectinib its first approval, for ROS1-positive NSCLC. Repotrectinib had been selected as a Molecule of the Month in 2021, well before either the acquisition or approval. What made this molecule scientifically notable? How is it better than past inhibitors, and how do we know? What else did Turning Point have in development, and what’s next for ROS1 inhibition? The full article explores the science behind repotrectinib and Turning Point: https://lnkd.in/g68-wgU5 Follow Drug Hunter to see more emerging molecules years before they’re approved.

ARG-007 has reached a number of key clinical milestones, with Argenica currently preparing for Stage 2 clinical trials later this year. Here are just a few things that sets ARG-007 apart when it comes to stroke therapeutics. To learn more, download our most recent Investor Presentation: https://bit.ly/3EpPzPO #ASX #AGN #ARG007 #stroketheraputics #clinicaltrials